MedTrace Logo

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

NCT05384249 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-02-21

No results posted yet for this study

Summary

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.

Conditions

  • Uveitis

Interventions

DRUG

Izokibep

Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC)

DRUG

Placebo

Form: Solution for injection Route of administration: Subcutaneous (SC)

Sponsors & Collaborators

  • ACELYRIN Inc.

    lead INDUSTRY

Principal Investigators

  • Donald Betah · ACELYRIN Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-23
Primary Completion
2025-02-07
Completion
2025-02-07
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Czechia
  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05384249 on ClinicalTrials.gov